Tinnitus-Pipeline Review, H1 2018

Tinnitus-Pipeline Review, H1 2018

  • Global Markets Direct
  • March 2018
  • Pharmaceutical
  • 61 pages
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tinnitus - Overview
Tinnitus - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Tinnitus - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tinnitus - Companies Involved in Therapeutics Development
AudioCure Pharma GmbH
Auris Medical Holding AG
Knopp Biosciences LLC
Otonomy Inc
Pragma Therapeutics SAS
SciFluor Life Sciences LLC
Sound Pharmaceuticals Inc
Tinnitus - Drug Profiles
AC-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AUT-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ebselen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
esketamine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gacyclidine SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GW-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GW-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RL-81 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SF-0034 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate KCNQ for Tinnitus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Kv7.2 for Central Nervous System Disorders and Tinnitus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Neurotrophic Factor for Tinnitus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize mGluR7 for Acute Sensorineural Hearing Loss, Presbycusis, and Tinnitus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit TNF-Alpha for Tinnitus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tetrandrine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tinnitus - Dormant Projects
Tinnitus - Discontinued Products
Tinnitus - Product Development Milestones
Featured News & Press Releases
Mar 13, 2018: Auris Medical Provides Business Update
Feb 26, 2018: Auris Medical to Host Key Opinion Leader Call Focused on Keyzilen Tinnitus Program on March 5, 2018
Feb 06, 2018: Otonomy Announces Multiple Presentations for Tinnitus Program at Upcoming Association for Research in Otolaryngology Meeting
Sep 22, 2017: Auris Medical Completes Patient Recruitment for Phase 3 TACTT3 Trial of Keyzilen in Acute and Post-Acute Tinnitus
May 09, 2017: Auris Medical Reports Key Results from Keyzilen AMPACT1 Open-Label Extension Study
Apr 24, 2017: Auris Medical Reports Key Results from Keyzilen AMPACT 2 Open-Label Extension Study
Mar 20, 2017: Sound Pharmaceuticals announces $1.6 Million Award from Cystic Fibrosis Foundation Therapeutics to prevent and treat the hearing loss and tinnitus associated with antibiotic use
Jan 26, 2017: Auris Medical Resumes Enrollment in TACTT3 Phase 3 Trial of Keyzilen in Acute and Post-Acute Tinnitus
Dec 06, 2016: Auris Medical on Track to Resume Enrollment of Keyzilen Tinnitus Program Following Regulatory Feedback
Oct 11, 2016: Auris Medical Provides Update on Development of Keyzilen for the Treatment of Acute Inner Ear Tinnitus
Oct 10, 2016: Auris Medical to Announce Keyzilen Program Update
Sep 01, 2016: PRAGMA Therapeutics and UK Ministry of Defences Center for Defence Enterprise collaborate to support preclinical research on innovative treatment for tinnitus
Aug 18, 2016: Auris Medical Reports Top-Line Results from TACTT2 Trial with Keyzilen in Acute Inner Ear Tinnitus
Jul 19, 2016: Auris Medical Secures Loan Facility of Up To $20 Million
Jul 18, 2016: FDA Grants Auris Medical Fast Track Designation for Keyzilen in Acute Peripheral Tinnitus
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Tinnitus, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Tinnitus - Pipeline by AudioCure Pharma GmbH, H1 2018
Tinnitus - Pipeline by Auris Medical Holding AG, H1 2018
Tinnitus - Pipeline by Knopp Biosciences LLC, H1 2018
Tinnitus - Pipeline by Otonomy Inc, H1 2018
Tinnitus - Pipeline by Pragma Therapeutics SAS, H1 2018
Tinnitus - Pipeline by SciFluor Life Sciences LLC, H1 2018
Tinnitus - Pipeline by Sound Pharmaceuticals Inc, H1 2018
Tinnitus - Dormant Projects, H1 2018
Tinnitus - Discontinued Products, H1 2018

List of Figures
Number of Products under Development for Tinnitus, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Have query on this report?

Success Stories

Our Clients

Tell Us What You Need and We’ll Get Back with the Best Solutions Available.

*
*
*

get in touch

Location :

State Tower, 90 State Street, Suite 700, Albany NY - 12207, United States

Call Us :

US/Canada toll free : 866-997-4948

Tel : +1-518-621-2074